Skip to main content

Advertisement

SpringerLink
Log in

Caution in Adding Bevacizumab in the Adjuvant Treatment of Breast Cancer

  • Medical Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ellis LM, Reardon DA. Cancer: the nuances of therapy. Nature 2009;458(7236):290–2.

    Article  CAS  PubMed  Google Scholar 

  2. Bahri S, Chen JH, Mehta RS, et al. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol. 2009;16:1619–28.

    Article  PubMed  Google Scholar 

  3. Roukos DH. Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn. 2009;9:217–21.

    Article  PubMed  Google Scholar 

  4. Roukos DH. Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn. 2009;9:227–9.

    Article  PubMed  Google Scholar 

  5. Roukos DH. Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol. 2009;16:772–3.

    Article  PubMed  Google Scholar 

  6. Roukos DH, Tzakos A, Zografos G. Current concerns and challenges towards tailored antiangiogenic therapy in cancer. Expert Rev Anticancer Ther. 2009;9(10):1413–6.

    Article  PubMed  Google Scholar 

  7. Roukos DH. Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg. 2009;249(6):1067–8.

    Article  PubMed  Google Scholar 

  8. Ziogas D, Roukos DH. Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol. 2009;16(7):1771–82.

    Article  PubMed  Google Scholar 

  9. Roukos DH. Genome-wide association studies: how predictable is a person's cancer risk? Expert Rev Anticancer Ther. 2009;9(4):389–92.

    Article  PubMed  Google Scholar 

  10. Roukos DH. Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol. 2009;27(8):1337–8.

    Article  PubMed  Google Scholar 

  11. Roukos DH. Radiation therapy for breast cancer. N Engl J Med. 2009;360(13):1362; author reply 1363.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, School of Medicine, University of Ioannina, Ioannina, Greece

    Dimosthenis Ziogas MD & Dimitrios Roukos MD

Authors
  1. Dimosthenis Ziogas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dimitrios Roukos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dimosthenis Ziogas MD.

Additional information

Published by Springer Science + Business Media, Inc. © 2009 The Society of Surgical Oncology, Inc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ziogas, D., Roukos, D. Caution in Adding Bevacizumab in the Adjuvant Treatment of Breast Cancer. Ann Surg Oncol 17, 653–654 (2010). https://doi.org/10.1245/s10434-009-0798-5

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-009-0798-5

Keywords

Search

Navigation